1. |
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures[J]. J Viral Hepat, 2004, 11(2): 97-107.
|
2. |
Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea[J]. Hepatology, 2000, 32(4 Pt 1): 803-806.
|
3. |
Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B[J]. Hepatology, 2003, 37(4): 748-755.
|
4. |
Ito K, Tanaka Y, Orito E, et al. Predicting relapse after cessation of Lamivudine monotherapy for chronic hepatitis B virus infection[J]. Clin Infect Dis, 2004, 38(4): 490-495.
|
5. |
中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南[J]. 中华肝脏病杂志, 2006, 9(1): 8-18.
|
6. |
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B[J]. J Hepatol, 2009, 50(2): 227-242.
|
7. |
Delaney WE 4th. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil[J]. J Antimicrob Chemother, 2007, 59(5): 827-832.
|
8. |
Lim SG, Cheng Y, Guindon S, et al. Viral quasi-species evolution during hepatitis Be antigen seroconversion[J]. Gastroenterology, 2007, 133(3): 951-958.
|
9. |
Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management[J]. Hepatology, 2007, 46(1): 254-265.
|
10. |
Sanchez MJ, Buti M, Homs M, et al. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab[J]. J Hepatol, 2009, 51(6): 1091-1096.
|
11. |
白浪,杨文斌,刘丽,等. 阿德福韦酯联合拉米夫定治疗阿德福韦酯应答不佳的慢性乙型肝炎的临床观察[J]. 华西医学, 2011, 26(9): 1281-1283.
|
12. |
刘锋,朱利红,孔亚兰,等.替比夫定联合阿德福韦酯治疗阿德福韦酯应答不佳的乙型肝炎病毒e抗原阳性慢性乙型肝炎患者[J]. 华西医学, 2012, 27(1): 14-17.
|